About: Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.19 (+0.92%)
ATHE NASDAQ Alterity Therapeutics Ltd
Alterity Therapeutics Ltd share price
Atividade de preço de ATHE
Último preço
$ 2,190
Variação (24h)
0,02 USD (0,92%)
Volume
572
Volume (média 4 sem.)
-
Abertura
$ 2,25
Variação do dia
$ 2,16 - $ 2,25
Fechamento anterior
$ 2,17
Último negócio
29 Oct, 2:31 pm GMT+0
Atrasado
29 Oct, 2:31 pm GMT+0
ATHE price performance
Atrasado
29 Oct, 2:31 pm GMT+0
quote.marketSignals